IGFBP7 and acute kidney injury: Kellum’s biomarker-driven innovation was exemplified in the PrevAKI trial, showing that urinary TIMP-2 and IGFBP7 guided KDIGO protocols reduced AKI incidence in high-risk patients, now a cornerstone of precision prevention (3).